CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients


Autoria(s): OLIVEIRA, Karen Brajao de; GUEMBAROVSKI, Roberta Losi; ODA, Julie Massayo Maeda; MANTOVANI, Mario Sergio; CARRERA, Clisia Mara; REICHE, Edna Maria Vissoci; VOLTARELLI, Julio Cesar; HERRERA, Ana Cristina da Silva do Amaral; WATANABE, Maria Angelica Ehara
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2011

Resumo

The role of chemokines has been extensively analyzed both in cancer risk and tumor progression. Among different cytokines, CXCR4 and its ligand CXCL12 have been recently subjected to a closer examination. The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/SDF1-3`A) in the CXCL12 gene and the relative expression of mRNA CXCL12 in peripheral blood were assessed in breast cancer patients, since the chemokine CXCL12 and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis and metastasis of different types of tumors. Genotyping was performed by PCR-RFLP (polymerase chain reaction followed by restriction fragment length polymorphism) using MspI restriction enzyme and the expression analyses by quantitative RT-PCR. No difference in GG genotype and allele A carrier frequencies were observed between breast cancer patients and healthy blood donors and nor when CXCL12 mRNA expression was assessed among patients with different tumor stages. However a significant difference was observed when CXCL12 mRNA relative expression was analyzed in breast cancer patients in accordance to the presence or absence of the CXCL12 rs1801157 allele A. Allele A breast cancer patients presented a mRNA CXCL12 expression about 2.1-fold smaller than GG breast cancer patients. Estrogen positive patients presenting CXCL12 allele A presented a significantly lower expression of CXCL12 in peripheral blood (p = 0.039) than GG hormone positive patients. Our findings demonstrated that allele A is associated with low expression of CXCL12 in the peripheral blood from ER-positive breast cancer patients, which suggests implications on breast cancer clinical outcome. (C) 2011 Elsevier Ltd. All rights reserved.

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Fundacao Araucaria

Programa Pesquisa para o SUS: gestao compartilhada em saude (PPSUS)

Londrina State University Coordination for Postgraduation (PROPPG-UEL)

Identificador

CYTOKINE, v.55, n.2, p.260-265, 2011

1043-4666

http://producao.usp.br/handle/BDPI/23928

10.1016/j.cyto.2011.04.017

http://dx.doi.org/10.1016/j.cyto.2011.04.017

Idioma(s)

eng

Publicador

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD

Relação

Cytokine

Direitos

restrictedAccess

Copyright ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD

Palavras-Chave #CXCL12 rs1801157 polymorphism #Estrogen receptor #Breast cancer #CELL-DERIVED FACTOR-1 #FACTOR-I SDF-1 #CHEMOKINE RECEPTORS #BONE-MARROW #MESSENGER-RNA #CXCR4 #METASTASIS #LYMPHOPOIESIS #MYELOPOIESIS #INDUCTION #Biochemistry & Molecular Biology #Cell Biology #Immunology
Tipo

article

original article

publishedVersion